0 229

Cited 10 times in

Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study

DC Field Value Language
dc.contributor.author조병철-
dc.date.accessioned2022-08-19T06:32:22Z-
dc.date.available2022-08-19T06:32:22Z-
dc.date.issued2019-03-
dc.identifier.issn0250-7005-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/189263-
dc.description.abstractBackground/Aim: The analysis of prognostic factors is important to identify determinants of disease-free survival (DFS) and overall survival (OS) in resected non-small-cell lung cancer (NSCLC). Patients and Methods: We examined baseline characteristics associated with DFS and OS among 757 patients with resected, histologically proven, MAGE-A3-positive Stage IB-IIIA NSCLC assigned to placebo in the MAGRIT study (NCT00480025). We explored characteristics of NSCLC that could predict DFS and OS using Cox regression models. Results: The multivariate analysis showed that lower nodal stage, the presence of squamous cell carcinoma (SCC), a broader surgical resection in patients with SCC, and being female with non-SCC were significantly associated with longer DFS. Lower nodal stage and smaller tumor size were significantly associated with an improved OS. Compared to Other International, enrollment in East Asia was associated with an improved OS in patients with non-SCC. Conclusion: This is the first prognostic factor analysis in NSCLC performed on data from a large prospective study. These results confirm retrospective studies and add that histopathology subtype is a strong determinant of DFS in resected MAGE-A3-positive NSCLC.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherInternational Institute of Anticancer Research-
dc.relation.isPartOfANTICANCER RESEARCH-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAged-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung / pathology*-
dc.subject.MESHDouble-Blind Method-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms / pathology*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPlacebos-
dc.subject.MESHPrognosis-
dc.subject.MESHSurvival Analysis-
dc.titlePrognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorByoung Chul Cho-
dc.contributor.googleauthorTommaso DE Pas-
dc.contributor.googleauthorHaralabos Kalofonos-
dc.contributor.googleauthorQun Wang-
dc.contributor.googleauthorRodryg Ramlau-
dc.contributor.googleauthorYing Cheng-
dc.contributor.googleauthorFabiana Vitiello-
dc.contributor.googleauthorTanel Laisaar-
dc.contributor.googleauthorEric Vallières-
dc.contributor.googleauthorBartosz Kubisa-
dc.contributor.googleauthorSergey Orlov-
dc.contributor.googleauthorKeunchil Park-
dc.contributor.googleauthorChanna Debruyne-
dc.contributor.googleauthorJohan Vansteenkiste-
dc.identifier.doi10.21873/anticanres.13255-
dc.contributor.localIdA03822-
dc.relation.journalcodeJ00188-
dc.identifier.eissn1791-7530-
dc.identifier.pmid30842175-
dc.identifier.urlhttps://ar.iiarjournals.org/content/39/3/1403.long-
dc.subject.keywordNon-small cell lung cancer-
dc.subject.keywordMAGE-A3 cancer immunotherapeutic-
dc.subject.keywordprognostic factors-
dc.subject.keywordplacebo-
dc.subject.keywordoverall survival-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.affiliatedAuthor조병철-
dc.citation.volume39-
dc.citation.number3-
dc.citation.startPage1403-
dc.citation.endPage1409-
dc.identifier.bibliographicCitationANTICANCER RESEARCH, Vol.39(3) : 1403-1409, 2019-03-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.